Summary of COVID-19 TRV027 studies
Studies
Meta Analysis
Hide extended summaries
Double-blind RCT 30 hospitalized COVID-19 patients in the United Kingdom showing a non-statistically significant trend towards decreased D-dimer levels with TRV027, an angiotensin-(1-7) analogue, compared to placebo. The trial was terminated early due to declining cases.
Dec 2022, British J. Clinical Pharmacology, https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.15618, https://c19p.org/robbins
Two RCTs of 510 hospitalized COVID-19 patients showing no significant difference in mortality or days alive without supplemental oxygen with either TRV027 (angiotensin II type 1 receptor-biased ligand) or TXA127 (synthetic angiotensin 1-7) compared to placebo.
Apr 2023, JAMA, https://jamanetwork.com/journals/jama/fullarticle/2803516, https://c19p.org/self5
1. Robbins et al., The effect of TRV027 on coagulation in COVID‐19: A pilot randomized, placebo‐controlled trial
28 patient TRV027 late treatment RCT: 73% higher mortality (p=1).Double-blind RCT 30 hospitalized COVID-19 patients in the United Kingdom showing a non-statistically significant trend towards decreased D-dimer levels with TRV027, an angiotensin-(1-7) analogue, compared to placebo. The trial was terminated early due to declining cases.
Dec 2022, British J. Clinical Pharmacology, https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.15618, https://c19p.org/robbins
2. Self et al., Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor–Biased Ligand in Adults With COVID-19
290 patient TRV027 late treatment RCT: 52% higher mortality (p=0.25) and 35% worse recovery (p=0.17).Two RCTs of 510 hospitalized COVID-19 patients showing no significant difference in mortality or days alive without supplemental oxygen with either TRV027 (angiotensin II type 1 receptor-biased ligand) or TXA127 (synthetic angiotensin 1-7) compared to placebo.
Apr 2023, JAMA, https://jamanetwork.com/journals/jama/fullarticle/2803516, https://c19p.org/self5
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.